Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic profiles of chimeric antigen receptor T cells with knockout of PRDM1

ABSTRACT: Epigenetic profiles of chimeric antigen receptor T cells with knockout of PRDM1

PROVIDER: PRJNA726408 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14368744_1.fastq.gz	Fastqsanger.gz
	SRR14368744_2.fastq.gz	Fastqsanger.gz
	SRR14368745_1.fastq.gz	Fastqsanger.gz
	SRR14368745_2.fastq.gz	Fastqsanger.gz
	SRR14368746_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Epigenetic profiles of chimeric antigen receptor T cells with knockout of PRDM1

Project description:Persistence of infused antitumor T cells is one of the essential factors for durable therapeutic response. T cells undergo genome-wide alterations in epigenetic architecture upon repeated antigen encounter, which is inevitably accompanied by progressive T cell differentiation and loss of longevity. In this study, we explored key epigenetic factors associated with terminal T cell differentiation using CRISPR/Cas9-mediated knockout of epigenetic genes in chimeric antigen receptor (CAR)-engineered human T cells and identified PRDM1 as one of the key epigenetic genes regulating T cell differentiation. We compared epigenetic profiles of control and PRDM1-knockout CAR-T cells by ATAC-sequencing analysis.

2022-05-17 | GSE173620 | GEO

chimeric antigen receptor T cells with knockout

Project description:chimeric antigen receptor T cells with knockout

| PRJNA727540 | ENA

Gene expression profiles of chimeric antigen receptor T cells with knockout of epigenetic genes

Project description:Persistence of infused antitumor T cells is one of the essential factors for durable therapeutic response. T cells undergo genome-wide alterations in epigenetic architecture upon repeated antigen encounter, which is inevitably accompanied by progressive T cell differentiation and loss of longevity. In this study, we explored key epigenetic factors associated with terminal T cell differentiation using CRISPR/Cas9-mediated knockout of epigenetic genes in chimeric antigen receptor (CAR)-engineered human T cells and identified multiple key epigenetic genes. We analyzed gene expression profiles of CAR-T cells that were knocked out with the specific epigenetic genes by RNA-sequencing.

2022-05-17 | GSE173918 | GEO

Epigenetic profiles of chimeric antigen receptor T cells

Project description:Epigenetic profiles of chimeric antigen receptor T cells

| PRJNA916209 | ENA

Gene expression profiles of chimeric antigen receptor T cells with knockout of epigenetic genes

Project description:Gene expression profiles of chimeric antigen receptor T cells with knockout of epigenetic genes

| PRJNA727547 | ENA

Phase I exploratory clinical study of CD276-targeted chimeric antigen receptor T cells for the treatment of solid tumors

Project description:Interventions: experimental group:CD276-targeted chimeric antigen receptor T cells Primary outcome(s): SAE rate Study Design: Single arm

| 2703905 | ecrin-mdr-crc

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

Project description:This clinical trial is an open-label, single-centre, dose escalation, phase I study designed to investigate the safety and tolerability of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Gamma Delta (γδ) T Cells (CTM-N2D) in Subjects with Relapsed or Refractory Solid Tumour. The study objectives of this phase I study are to determine the safety, activity and the safe dose of haploidentical or allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T cells given four times weekly in patients with relapsed or refractory solid tumors of different types.

| 2317628 | ecrin-mdr-crc

Prdm1

Project description:Prdm1

| PRJNA300302 | ENA

Expression data from chimeric antigen receptor transduced (CAR) human CD4+ T cells during expansion

Project description:In this data set we include expression data from human CD4+ T cells isolated on day 0, 6, 11 and 24 follow anti-CD3/anti-CD28 magnetic bead stimulation and chimeric antigen receptor transduction.

2015-01-14 | GSE64914 | GEO

Expression data from mouse CD19-targeted CAR (chimeric antigen receptor) T cells after antigen stimulation [expression array]

Project description:Second-generation CD19-targeted chimeric antigen receptors (CAR) have an antigen-binding domain fused to transmembrane, co-stimulatory, and CD3ζ domains. The two CARs with regulatory approval include a CD28 or 4-1BB co-stimulatory domain. While both CARs achieve similar clinical outcomes, biologic differences between the two endodomains have become apparent but not completely understood. The objective is to evaluate gene expression in different mouse CD19-targeted CAR T cells, including m19z, m1928z and m19-musBBz.

2018-07-31 | GSE111641 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data